Does NIVOLUMAB Cause Hyperammonaemic encephalopathy? 15 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Hyperammonaemic encephalopathy have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.0% of all adverse event reports for NIVOLUMAB.
15
Reports of Hyperammonaemic encephalopathy with NIVOLUMAB
0.0%
of all NIVOLUMAB reports
1
Deaths
14
Hospitalizations
How Dangerous Is Hyperammonaemic encephalopathy From NIVOLUMAB?
Of the 15 reports, 1 (6.7%) resulted in death, 14 (93.3%) required hospitalization, and 13 (86.7%) were considered life-threatening.
Is Hyperammonaemic encephalopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Hyperammonaemic encephalopathy?
VALPROIC ACID (455)
FLUOROURACIL (156)
VALPROATE (120)
DIVALPROEX (119)
OXALIPLATIN (107)
TOPIRAMATE (101)
RISPERIDONE (96)
QUETIAPINE (91)
LEVETIRACETAM (71)
LEUCOVORIN (62)
Which NIVOLUMAB Alternatives Have Lower Hyperammonaemic encephalopathy Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE